Sanofi-Aventis CEO Christopher A. Viehbacher said Genzyme's focus on patients and open partnerships are some of the characteristics that could benefit Sanofi, while the latter's global sales force and other resources could help Genzyme. Although there still are many business decisions to make, Viehbacher said, Sanofi plans to support the development of Genzyme's three drug candidates, including a treatment for Niemann-Pick disease, that have been halted after the firm focused its attention addressing manufacturing issues.

Related Summaries